PeriVision's VR Platform: Revolutionizing Eye Diagnostics with AI

PeriVision's VR Platform: A New Standard in Eye Diagnostics

PeriVision, a spin-off from the University of Bern and Inselspital, has secured CHF 2.4 million in seed funding to further develop its innovative VR eye testing platform, VisionOne. This investment, led by ARYA VC and supported by several other venture funds, family offices, and business angel networks, is poised to revolutionize the way glaucoma and retinal diseases are diagnosed and managed.

The VisionOne Platform: Combining VR and AI

The VisionOne platform is a breakthrough in eye diagnostics, utilizing commercial VR headsets and advanced AI algorithms to deliver faster, more accurate, and patient-friendly visual field tests. Traditional methods often require specialized equipment, are time-consuming, and can be resource-intensive, limiting their accessibility. VisionOne, on the other hand, offers a more streamlined and efficient solution.

Key Features and Benefits

• Faster Testing**: VisionOne significantly reduces the time required for visual field tests, making it more practical for both patients and healthcare providers.
• Enhanced Accuracy**: The platform's AI algorithms analyze test results with high precision, improving the reliability of diagnoses.
• Patient-Friendly**: VR technology makes the testing process more engaging and less stressful for patients, particularly children and the elderly.
• Scalability**: VisionOne is designed for use in various settings, including clinics, optometry practices, and biopharma research, making it highly versatile.

Expanding the Clinical Offering

With the new funding, PeriVision plans to develop additional retina disease tests and advanced AI insights. This expansion will further enhance the platform's capabilities and broaden its application in healthcare. The company also aims to integrate VisionOne with existing healthcare systems, facilitating seamless data exchange and improving patient care.

Global Impact

Glaucoma and other eye diseases are major public health concerns, affecting millions of people worldwide. Late diagnosis often leads to irreversible blindness, making early and accurate detection crucial. VisionOne's ability to provide rapid and reliable tests can significantly improve outcomes for over 100 million glaucoma patients globally. By reducing the burden on healthcare systems, the platform also contributes to more efficient and cost-effective care.

Early Adoption and Market Traction

PeriVision has already gained traction in multiple European markets, supported by early commercial adoption and distribution agreements. The company's achievements, including CE marking and a CHF 300,000 FIT loan, have solidified its position as a leading healthtech innovator in Western Switzerland. The addition of Arijana Walcott and Sanem Tatlidil Özal to the board and observer roles, respectively, brings valuable expertise in scaling technology and healthcare ventures.

The Role of Funding

The seed funding will be instrumental in accelerating PeriVision's growth and innovation. Key areas of focus include:

1. Developing New Tests: Expanding the range of retina disease tests to cover a broader spectrum of conditions.
2. Enhancing AI Insights: Refining the AI algorithms to provide more detailed and actionable insights for healthcare providers.
3. System Integrations: Integrating VisionOne with existing healthcare systems to ensure seamless data flow and improved patient care.
4. Global Expansion: Scaling the platform's reach to new markets, including the US and UK, where it is already certified.

Projections and Future Outlook

Projections suggest that the global market for eye diagnostics will see a significant increase in the coming years, driven by advancements in technology and a growing awareness of the importance of early detection. VisionOne is well-positioned to capitalize on this trend, offering a solution that addresses key challenges in the field.

The Bottom Line

PeriVision's VisionOne platform represents a significant leap forward in eye diagnostics. By combining VR and AI, the company is setting a new standard for accuracy, efficiency, and patient satisfaction. With the support of strategic funding and a strong team, PeriVision is poised to make a substantial impact on global eye health and transform the way we approach glaucoma and retinal disease diagnosis.